Active	Status	Sponsor type	Region	Phase	Filter
23 Active 9 Inactive 32 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Goldberg, David
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab	Active, not recruiting	3	120	US	Lebrikizumab, LY3650150, DRM06	Eli Lilly and Company	Atopic Dermatitis	01/24	02/25
PLATyPuS, NCT02315898: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis	Completed	2	40	US	Treatment-inhaled tPA, alteplase, Activase	University of Michigan, Genentech, Inc.	Plastic Bronchitis, Protein-Losing Enteropathies, Healthy	03/21	06/23
NCT04844840: A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence	Completed	2	29	US	STP705, STP705 Powder for Injection, Placebo	Sirnaomics	Keloid	05/23	05/23
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC	Completed	2	44	US	STP705, STP705 Powder for Injection, Placebo Saline	Sirnaomics	Squamous Cell Carcinoma in Situ	08/22	12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	2	75	US	LY3972406, Placebo	Eli Lilly and Company	Plaque Psoriasis	04/25	07/25
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients	Active, not recruiting	2	201	US	Epclusa	University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	End Stage Renal Disease	06/25	01/26
FALD, NCT03430583: Evaluation of Fontan-Associated Liver Disease	Active, not recruiting	N/A	100	Canada, US	MZ101	Mezzion Pharma Co. Ltd, National Heart, Lung, and Blood Institute (NHLBI)	Single Ventricle Heart Disease	06/21	08/21
NCT05358860: Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement	Completed	N/A	60	US	Sofwave, SUPERB	Sofwave Medical LTD	Acne Scars - Mixed Atrophic and Hypertrophic	12/22	12/22
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator	Completed	N/A	60	US	Sofwave	Sofwave Medical LTD	Cellulite	11/23	11/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/24	12/25
Zarrinpar, Ali
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients	Active, not recruiting	2	201	US	Epclusa	University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	End Stage Renal Disease	06/25	01/26
TGI, NCT06063213: Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation	Recruiting	N/A	40	US		University of Florida, Transplant Genomics, Inc.	Transplant Complication	10/26	10/26
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry	Active, not recruiting	N/A	5000	US	Prospera	Natera, Inc., University of Maryland	Kidney Transplant Rejection	10/26	10/27